Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VA Induction and CD19/CD22 CAR-T for High-Risk Ph- B-ALL
NCT06078306Phase 2Unknown
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Apr 2024
- Primary completion
- Sep 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CD19/CD22 CAR-T in B cell acute lymphoblastic leukemia (B-ALL), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Complete Remission Rate. Status: unknown.
02
Drugs
CD19/CD22 CAR-T
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06078306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06078306.